Find Clinical Trials

June 20, 2024 in Other Sites

ES2021-05 – Contact MMCORC for more information

Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
Read More
February 19, 2024 in Other Sites

SGNDV-005

A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Read More
October 30, 2023 in Other Sites

EAY191-E4

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors (NCT #05554341)
Read More
June 14, 2023 in Other Sites

EAY191-S3

Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors
Read More
May 10, 2023 in Other Sites

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Read More
September 7, 2022 in Other Sites

TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
Read More
July 11, 2022 in Other Sites

U19075

U19075: Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Read More
July 11, 2022 in Other Sites

S2012

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Read More
July 11, 2022 in Other Sites

S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Read More
July 1, 2022 in Other Sites

Mirati/KRYSTAL-1

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Read More
June 30, 2022 in Other Sites

A151804

A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Read More
June 29, 2022 in Other Sites

A021804

A021804: A prospective, multi-institutional phase II trial evaluating temozolomide vs. temozolomide and olaparib for advanced pheochromocytoma and paraganglioma, NCT04394858
Read More